vs
Avantor, Inc.（AVTR）与Prenetics Global Ltd（PRE）财务数据对比。点击上方公司名可切换其他公司
Avantor, Inc.的季度营收约是Prenetics Global Ltd的387.3倍（$1.7B vs $4.3M）
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
Prenetics是一家总部位于中国香港的健康科学企业，业务辐射美国地区，专注于癌症等疾病的早期筛查、预防与干预诊疗，致力于帮助人们更早发现健康风险，助力提升相关疾病的治疗效果，推动肿瘤等重疾的早防早治，守护公众健康。
AVTR vs PRE — 直观对比
营收规模更大
AVTR
是对方的387.3倍
$4.3M
损益表 — Q4 2025 vs Q3 2023
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $4.3M |
| 净利润 | $52.4M | — |
| 毛利率 | 31.5% | 44.9% |
| 营业利润率 | 7.6% | -396.2% |
| 净利率 | 3.1% | — |
| 营收同比 | -1.4% | — |
| 净利润同比 | -89.5% | — |
| 每股收益（稀释后） | $0.08 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVTRPRE
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.7B | — | ||
| Q1 24 | $1.7B | — |
净利润AVTRPRE
| Q4 25 | $52.4M | — | ||
| Q3 25 | $-711.8M | — | ||
| Q2 25 | $64.7M | — | ||
| Q1 25 | $64.5M | — | ||
| Q4 24 | $500.4M | — | ||
| Q3 24 | $57.8M | — | ||
| Q2 24 | $92.9M | — | ||
| Q1 24 | $60.4M | — |
毛利率AVTRPRE
| Q4 25 | 31.5% | — | ||
| Q3 25 | 32.4% | — | ||
| Q2 25 | 32.9% | — | ||
| Q1 25 | 33.8% | — | ||
| Q4 24 | 33.4% | — | ||
| Q3 24 | 32.9% | — | ||
| Q2 24 | 34.1% | — | ||
| Q1 24 | 34.0% | — |
营业利润率AVTRPRE
| Q4 25 | 7.6% | — | ||
| Q3 25 | -40.0% | — | ||
| Q2 25 | 7.7% | — | ||
| Q1 25 | 9.3% | — | ||
| Q4 24 | 37.8% | — | ||
| Q3 24 | 7.3% | — | ||
| Q2 24 | 10.3% | — | ||
| Q1 24 | 8.7% | — |
净利率AVTRPRE
| Q4 25 | 3.1% | — | ||
| Q3 25 | -43.8% | — | ||
| Q2 25 | 3.8% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 29.7% | — | ||
| Q3 24 | 3.4% | — | ||
| Q2 24 | 5.5% | — | ||
| Q1 24 | 3.6% | — |
每股收益（稀释后）AVTRPRE
| Q4 25 | $0.08 | — | ||
| Q3 25 | $-1.04 | — | ||
| Q2 25 | $0.09 | — | ||
| Q1 25 | $0.09 | — | ||
| Q4 24 | $0.73 | — | ||
| Q3 24 | $0.08 | — | ||
| Q2 24 | $0.14 | — | ||
| Q1 24 | $0.09 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $365.4M | — |
| 总债务越低越好 | $3.9B | — |
| 股东权益账面价值 | $5.6B | — |
| 总资产 | $11.8B | — |
| 负债/权益比越低杠杆越低 | 0.71× | — |
8季度趋势，按日历期对齐
现金及短期投资AVTRPRE
| Q4 25 | $365.4M | — | ||
| Q3 25 | $251.9M | — | ||
| Q2 25 | $449.4M | — | ||
| Q1 25 | $315.7M | — | ||
| Q4 24 | $261.9M | — | ||
| Q3 24 | $285.3M | — | ||
| Q2 24 | $272.6M | — | ||
| Q1 24 | $234.9M | — |
总债务AVTRPRE
| Q4 25 | $3.9B | — | ||
| Q3 25 | $3.9B | — | ||
| Q2 25 | $4.2B | — | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $4.9B | — | ||
| Q2 24 | $5.1B | — | ||
| Q1 24 | $5.3B | — |
股东权益AVTRPRE
| Q4 25 | $5.6B | — | ||
| Q3 25 | $5.6B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $6.1B | — | ||
| Q4 24 | $6.0B | — | ||
| Q3 24 | $5.6B | — | ||
| Q2 24 | $5.4B | — | ||
| Q1 24 | $5.3B | — |
总资产AVTRPRE
| Q4 25 | $11.8B | — | ||
| Q3 25 | $11.7B | — | ||
| Q2 25 | $12.8B | — | ||
| Q1 25 | $12.3B | — | ||
| Q4 24 | $12.1B | — | ||
| Q3 24 | $12.8B | — | ||
| Q2 24 | $12.7B | — | ||
| Q1 24 | $12.8B | — |
负债/权益比AVTRPRE
| Q4 25 | 0.71× | — | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 0.68× | — | ||
| Q3 24 | 0.89× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | 1.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | — |
| 自由现金流经营现金流 - 资本支出 | $117.2M | — |
| 自由现金流率自由现金流/营收 | 7.0% | — |
| 资本支出强度资本支出/营收 | 2.1% | — |
| 现金转化率经营现金流/净利润 | 2.91× | — |
| 过去12个月自由现金流最近4个季度 | $495.0M | — |
8季度趋势，按日历期对齐
经营现金流AVTRPRE
| Q4 25 | $152.7M | — | ||
| Q3 25 | $207.4M | — | ||
| Q2 25 | $154.4M | — | ||
| Q1 25 | $109.3M | — | ||
| Q4 24 | $173.3M | — | ||
| Q3 24 | $244.8M | — | ||
| Q2 24 | $281.1M | — | ||
| Q1 24 | $141.6M | — |
自由现金流AVTRPRE
| Q4 25 | $117.2M | — | ||
| Q3 25 | $171.7M | — | ||
| Q2 25 | $124.8M | — | ||
| Q1 25 | $81.3M | — | ||
| Q4 24 | $145.8M | — | ||
| Q3 24 | $204.0M | — | ||
| Q2 24 | $235.3M | — | ||
| Q1 24 | $106.9M | — |
自由现金流率AVTRPRE
| Q4 25 | 7.0% | — | ||
| Q3 25 | 10.6% | — | ||
| Q2 25 | 7.4% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 8.6% | — | ||
| Q3 24 | 11.9% | — | ||
| Q2 24 | 13.8% | — | ||
| Q1 24 | 6.4% | — |
资本支出强度AVTRPRE
| Q4 25 | 2.1% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 2.7% | — | ||
| Q1 24 | 2.1% | — |
现金转化率AVTRPRE
| Q4 25 | 2.91× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 1.69× | — | ||
| Q4 24 | 0.35× | — | ||
| Q3 24 | 4.24× | — | ||
| Q2 24 | 3.03× | — | ||
| Q1 24 | 2.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
PRE
暂无分部数据
